Alnylam Pharma (ALNY) Tops Q4 EPS by 64c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $161.18 +0.81%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $0.06, $0.64 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $593.16 million versus the consensus estimate of $580.61 million.
GUIDANCE:
Alnylam Pharma sees FY2025 revenue of $2.05-2.25 billion, versus the consensus of $2.68 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- Datadog shares drop on weak Q4 revenue outlook
- Netflix gains after Ackman endorsement and AI feature launch
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
